| In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes HJ Lachmann, P Lowe, SD Felix, C Rordorf, K Leslie, S Madhoo, ... Journal of Experimental Medicine 206 (5), 1029-1036, 2009 | 388 | 2009 |
| Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects JP Arm, I Bottoli, A Skerjanec, D Floch, A Groenewegen, S Maahs, ... Clinical & Experimental Allergy 44 (11), 1371-1385, 2014 | 264 | 2014 |
| Omalizumab in asthma: an update on recent developments M Humbert, W Busse, NA Hanania, PJ Lowe, J Canvin, VJ Erpenbeck, ... The Journal of Allergy and Clinical Immunology: In Practice 2 (5), 525-536. e1, 2014 | 248 | 2014 |
| Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats PJ LOWE, CS TEMPLE Journal of pharmacy and pharmacology 46 (7), 547-552, 1994 | 241 | 1994 |
| Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1 Monoclonal Antibody A Chakraborty, S Tannenbaum, C Rordorf, PJ Lowe, D Floch, H Gram, ... Clinical Pharmacokinetics 51 (6), e1-e18, 2012 | 199 | 2012 |
| A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab N Hayashi, Y Tsukamoto, WM Sallas, PJ Lowe British journal of clinical pharmacology 63 (5), 548-561, 2007 | 196 | 2007 |
| Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthma PJ Lowe, S Tannenbaum, A Gautier, P Jimenez British journal of clinical pharmacology 68 (1), 61-76, 2009 | 175 | 2009 |
| Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations RG Slavin, C Ferioli, SJ Tannenbaum, C Martin, M Blogg, PJ Lowe Journal of Allergy and Clinical Immunology 123 (1), 107-113. e3, 2009 | 166 | 2009 |
| Omalizumab decreases IgE production in patients with allergic (IgE‐mediated) asthma; PKPD analysis of a biomarker, total IgE PJ Lowe, D Renard British journal of clinical pharmacology 72 (2), 306-320, 2011 | 161 | 2011 |
| Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2 [2-(-4-octylphenyl) ethyl] propane-1, 3-diol hydrochloride) in rats after oral and intravenous doses GML Meno-Tetang, H Li, S Mis, N Pyszczynski, P Heining, P Lowe, ... Drug metabolism and disposition 34 (9), 1480-1487, 2006 | 152 | 2006 |
| Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses GM Gauvreau, JP Arm, LP Boulet, R Leigh, DW Cockcroft, BE Davis, ... Journal of Allergy and Clinical Immunology 138 (4), 1051-1059, 2016 | 144 | 2016 |
| Membrane lipid composition and susceptibility to bile salt damage R Coleman, PJ Lowe, D Billington Biochimica et Biophysica Acta (BBA)-Biomembranes 599 (1), 294-300, 1980 | 138 | 1980 |
| Hormonal regulation of hepatocyte tight junctional permeability PJ Lowe, K Miyai, JH Steinbach, WGM Hardison Am J Physiol 255 (4 Pt 1), G454-G461, 1988 | 135 | 1988 |
| The effects of colchicine on secretion into bile of bile salts, phospholipids, cholesterol and plasma membrane enzymes: bile salts are secreted unaccompanied by phospholipids … SG Barnwell, PJ Lowe, R Coleman Biochemical Journal 220 (3), 723-731, 1984 | 127 | 1984 |
| On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach GML Meno‐Tetang, PJ Lowe Basic & clinical pharmacology & toxicology 96 (3), 182-192, 2005 | 113 | 2005 |
| Transcytosis and paracellular movements of horseradish peroxidase across liver parenchymal tissue from blood to bile. Effects of alpha-naphthylisothiocyanate and colchicine PJ Lowe, KS Kan, SG Barnwell, RK Sharma, R Coleman Biochemical Journal 229 (2), 529-537, 1985 | 100 | 1985 |
| On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development PJ Lowe, Y Hijazi, O Luttringer, H Yin, R Sarangapani, D Howard Xenobiotica 37 (10-11), 1331-1354, 2007 | 88 | 2007 |
| Rapid kinetic analysis of the bile-salt-dependent secretion of phospholipid, cholesterol and a plasma-membrane enzyme into bile PJ Lowe, SG Barnwell, R Coleman Biochemical Journal 222 (3), 631-637, 1984 | 86 | 1984 |
| On Setting the First Dose in Man: Quantitating Biotherapeutic Drug‐Target Binding through Pharmacokinetic and Pharmacodynamic Models PJ Lowe, S Tannenbaum, K Wu, P Lloyd, J Sims Basic & clinical pharmacology & toxicology 106 (3), 195-209, 2010 | 84 | 2010 |
| Membrane fluidity and bile salt damage PJ Lowe, R Coleman Biochimica et Biophysica Acta (BBA)-Biomembranes 640 (1), 55-65, 1981 | 83 | 1981 |
Jonathan Peter ArmBill & Melinda Gates FoundationVerified email at gatesfoundation.org
